Lipid- and adenoviral-mediated gene transfer into AIDS-Kaposi's sarcoma cell lines

Cancer Gene Therapy

Volumn 5, Issue 3, 1998, Pages 131-143

  Campain, Julie A ^a,d   Matassa, Angela A ^a   Felgner, Philip L ^b   Barnhart, Kerry M ^b   Curiel, David T ^c   Harrison, Gail S ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VICAL INC   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adenoviral gene transfer; Gene therapy; Kaposi's sarcoma; Liposomes

Indexed keywords

DNA; LIPID; LIPOSOME;

ADENOVIRUS; AIDS RELATED COMPLEX; ARTICLE; CELL CULTURE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GENETICS; HUMAN; KAPOSI SARCOMA; PATHOLOGY; PROMOTER REGION;

ADENOVIRIDAE; AIDS-RELATED OPPORTUNISTIC INFECTIONS; DNA; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LIPIDS; LIPOSOMES; PROMOTER REGIONS (GENETICS); SARCOMA, KAPOSI; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032065217     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Mitsuyasu RT, Groopman JE. Biology and therapy of Kaposi's sarcoma. Semin Oncol. 1984;11(1):53-59.
2. Safai B, Johnson KG, Myskowski PL, et al. The natural history of KS in acquired immunodeficiency syndrome. Ann Intern Med. 1985;103:744-750.
3. Safai B. Pathophysiology and epidemiology of epidemic Kaposi's sarcoma. Semin Oncol. 1987;14(Suppl. 3):7-12.
4. Hill DR. The role of radiotherapy for epidemic Kaposi's sarcoma. Semin Oncol. 1987;14(Suppl. 3):19-22.
5. Krown SE. The role of interferon in the therapy of epidemic Kaposi's sarcoma. Semin Oncol. 1987;14(Suppl. 3):27-33.
6. Northfelt DW, Volberding PA. AIDS-related Kaposi's sarcoma: clinical presentation, biology, and therapy. Adv Oncol. 1991;7:9-17.
7. Volberding PA. The role of chemotherapy for epidemic Kaposi's sarcoma. Semin Oncol. 1987;14(Suppl. 3):23-26.
8. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 1993;53:3860-3864.
9. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity and lack of toxicity in humans. Proc Natl Acad Sci USA. 1993;90(23):11307-11311.
10. Nabel EG, Yang Z, Muller D, et al. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum Gene Ther. 1994; 5:1089-1094.
11. Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science. 1993;261:209-211.
12. Francis ND, Parkin JM, Weber J, Boylston AW. Kaposi's sarcoma in acquired immune deficiency syndrome (AIDS). J Clin Pathol 1986;39:469-474.
13. Huang SK, Martin FJ, Jay GJ, Vogel J, Papahadjopoulos D, Friend DS. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV Tat gene. Am J Pathol. 1993;143:10-14.
14. Northfelt DW, Martin FJ, Kaplan LD, Russell J, Anderson M, Lang J, Volberding PA. Pharmacokinetics, tumor localization, and safety of doxil (liposomal doxorubicin) in AIDS patients with Kaposi's sarcoma. Proc Am Soc Clin Onco. 1993;12:51.
15. Templeton AC. Kaposi's Sarcoma: Pathophysiology and Clinical Management. New York: Marcel Dekker; 1998.
16. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA. 1993;90:2812-2816.
17. Ross G, Erickson R, Knorr D, et al. Gene therapy in the United States: a five-year status report. Hum Gene Ther. 1996;7:1781-1790.
18. Chapman BS, Thayer RM, Vincent KA, Haigwood NL. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 1991;19:3979-3986.
19. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259(5102):1745-1749.
20. Liang X, Hartikka J, Sukhu L, Manthorpe M, Hobart P. Novel high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy. Gene Ther. 1996;3:350-356.
21. Felgner PL, Tasai YJ, Sukhu L, Wheeler CJ, Manthorpe M. Improved cationic lipid formulations for in vivo gene therapy. Ann N Y Acad Sci. 1995;772:126-139.
22. Hawley-Nelson PV, Ciccarone V, Gebeyehu G, Jessee J, Feigner PL. Lipofectamine reagent: a new higher efficiency polycationic liposome transfection reagent. Focus. 1993;15:73-79.
23. Browning PJ, Roberts DD, Zabrenetzky V, et al. T apolipoprotein E (Apo E), a novel heparin-binding protein, inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice. J Exp Med. 1994;180(5):1949-1954.
24. + T cells. Science. 1988;242:426-429.
25. Salahuddin SZ, Nakamura S, Biberfeld P, Kaplan MH, Markham PD, Larsson L, Gallo RC. Angiogenic properties of Kaposi's sarcoma-derived cells after long term culture in vitro. Science. 1988;242:430-433.
26. Lunardi-Iskandar Y, Gill P, Lam VH, et al. Isolation and characterization of an immortal neoplastic cell line (KS Y-1) from AIDS-associated Kaposi's sarcoma. J Natl Cancer Inst. 1995;87(13):974-981.
27. Siegal B, Levinton-Kriss S, Schiffer A, et al. Kaposi's sarcoma in immunosuppression: possibly the result of a dual viral infection. Cancer. 1990;65:492-498.
28. Miles SA, Martinez-Maza O, Rezai A, et al. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science. 1992;255(5050):1432-1434.
29. Nair BC, DeVico AL, Nakamura S, et al. Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science. 1992;255:1430-1436.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
31. Maxwell IH, Maxwell F. Electroporation of mammalian cell with a firefly luciferase expression plasmid: kinetics of transient expression differ markedly among cell types DNA. 1988;7(8):557-562.
32. Sancs JR, Rubenstein JL, Nicolas JF. Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J. 1986;5(12):3133-3142.
33. + hematopoietic cells. Biotechniques. 1995;19:816-823.
34. Masood R, Husain SR, Rahman A, Gill P. Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome encapsulated doxorubicin. AIDS Res Hum Retrovir. 1993;9(8):741-746.
35. Zabner J, Fasbender, AJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem. 1995;270(32):18997-19007.
36. Wu CH, Wilson JM, Wu GY. Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J Biol Chem. 1992;264:16985-16987.
37. Wilson JM, Grossman, M, Cabrera JA, Wu CH, Wu GY. A novel mechanism for achieving transgene persistence in vivo after somatic gene transfer into hepatocytes. J Biol Chem. 1992;267(16):11483-11489.
38. r carrier DNA in synchronized CV-1 cells. Biochein J. 1985;225:529-533.
39. Nicolau C, Sene C. Liposome-mediated DNA transfer in eukaryotic cells. Biochem Biophys Acta. 1982;721:185-190.
40. Lemarchand P, Ari Jaffe H, Danel C, et al. Adenovirus-mediated transfer of a recombinant human al-antitrypsin cDNA to human endothelial cells. Proc Natl Acad Sci USA. 1992;89:6482-6486.
41. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res. 1993;(72):1132-1138.
42. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320-1323.
43. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 1997;57(8): 1447-1451.
44. Li JJ, Huang YQ, Moscatelli D, Nicolaides A, Zhang WC, Friedman-Kien AE. Expression of fibroblast growth factors and their receptors in acquired immunodeficiency syndrome-associated Kaposi sarcoma tissue and derived cells. Cancer. 1993;72:2253-2259.
45. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA. 1993;90:7941-7945.
46. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 1994; 371:674-680.
47. Michael SI, Huang CH, Romer MU, Wagner E, Hu PC, Curiel DT. Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. J Biol Chem. 1993; 268(10):6866-6869.
48. Douglas JT, Curiel DT. Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. Neuromuscul Disord. 1997;7(5):284-298.
49. Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann N Y Acad Sci. 1994;716:90-103.
50. Weindel K, Marme D, Weich HA. AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. Biochem Biophys Res Commun. 1992;183(3):1167-1174.
51. Ensoli B, Nakamura S, Salahuddin SZ, et al. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science. 1989;243: 223-226.
52. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996;380:364-366.
53. Schumacher TN, Mayr LM, Minor DL, Milhollen MA, Burgess MW, Kim PS. Identification of D-peptide ligands through mirror-image phage display. Science. 1996;271: 1854-1857.
54. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med. 1996;2:299-305.